|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations.
|
21869714 |
2011 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
|
30870512 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.
|
28448232 |
2017 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
|
27029623 |
2016 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGFR amplification was focally distributed in lung cancer specimens, mostly in regions with solid histology.
|
19826035 |
2009 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that CytoRich Red is not only suitable for ICC with EGFR mutation-specific antibodies, but also for DNA analysis of cytological material, and is useful in molecular testing of lung cancer, for which various types of analyses will be needed in future.
|
24167084 |
2014 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have demonstrated the feasibility of the compact SPR biosensor in lung cancer diagnosis using exosomal epidermal growth factor receptor (EGFR) and programmed death-ligand 1 (PD-L1) as biomarkers.
|
30019892 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
By optimizing competitive allele-specific TaqMan PCR (CAST-PCR), we assessed the copy number of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) alleles in the pre/post surgery plasma of 168 lung cancer patients.
|
28382702 |
2017 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, the mutation does not significantly alter the Km for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed.
|
23612964 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for EGFR, ALK and ROS1 genetic mutation analysis in patients with adenocarcinoma or not otherwise specified (NOS) lung cancer.
|
30582673 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to EGFR-TKIs and other targeted therapies.
|
22664249 |
2012 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
We used multiple lung cancer cell lines to develop and characterize EGFR:GRB2 PLA and correlated this assay with established biochemical measures of EGFR signaling.
|
25587191 |
2015 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
It is now established that EGFR-tyrosine kinase inhibitor treatment (erlotinib and geftinib) in lung cancer is more effective in LCINS, owing to the higher incidence of EGFR mutation in nonsmokers.
|
21992731 |
2011 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies.
|
30679984 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to clarify the correlation between the EGFR mutation status and the prevalence of underlying lung disease in smokers with lung cancer.
|
23467672 |
2013 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our result may provide an insight into the association of mutant EGFR and CDH5 expression in lung cancer and aid further development of target therapy for NSCLC in the future.
|
27362942 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
GMI induced apoptosis in lung cancer cells bearing wild-type and mutated EGFR.
|
29974605 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
|
15284455 |
2004 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR.
|
29050315 |
2017 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
|
21960227 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms.
|
29967248 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer.
|
30580903 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
|
25653196 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data may suggest that gefitinib should be preferred to erlotinib for the treatment of pregnant woman with lung cancer harboring an EGFR-activating mutation, during the second and third trimesters of pregnancy.
|
25851627 |
2015 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Drug resistance is a major challenge for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment of lung cancer.
|
31417255 |
2019 |